Autres langues BioNTech SE

Actions

BNTX

US09075V1026

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 18/09/2026			Varia. 5j.	Varia. 1 janv.
96,06 ^USD	-2,64%		-0,69%	+0,90%

18/09	Biontech : un initié cède des actions pour une valeur de 6 239 071 $, selon un récent dépôt auprès de la SEC	MT
18/09	Les actions européennes cotées aux États-Unis sous forme d'ADR reculent lors de la séance de vendredi	MT

Autres langues

18/09	Biontech Insider Sold Shares Worth $6,239,071, According to a Recent SEC Filing
18/09	European Equities Traded in the US as American Depositary Receipts Drop in Friday Trading
17/09	Pfizer Canada ULC And BioNTech SE Receive Health Canada Authorization For Omicron XFG-Adapted COMIRNATY COVID-19 Vaccine
17/09	Pfizer, BioNTech Secure Health Canada Authorization for Omicron XFG-Adapted COVID-19 Vaccine
17/09	Health Canada Authorizes Pfizer and BioNTech's Omicron XFG-Adapted COVID-19 Vaccine
16/09	Biontech Insider Sold Shares Worth $4,721,976, According to a Recent SEC Filing
16/09	Berenberg hebt Ziel für Biontech auf 140 Dollar - 'Buy'
15/09	European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
14/09	BioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer
14/09	BioNTech, OncoC4's Gotistobart Boosts Survival in Non-small Cell Lung Cancer Study
14/09	BioNTech verzeichnet Etappenerfolg mit neuem Lungenkrebsmittel
14/09	BioNTech says lung cancer drug candidate prolonged lives in trial
14/09	BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
14/09	Neue Daten zu Gotistobart zeigten annähernde Verdopplung des medianen Gesamtüberlebens im Vergleich zur Standardchemotherapie bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge
14/09	BioNTech And OncoC4 Present Updated Data Showing Gotistobart Nearly Doubles Median Overall Survival Versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
11/09	Biontech Insider Sold Shares Worth $1,974,287, According to a Recent SEC Filing
10/09	European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading
08/09	Biontech Insider Sold Shares Worth $7,889,055, According to a Recent SEC Filing
08/09	European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
04/09	European Equities Traded in the US as American Depositary Receipts Marginally Higher in Friday Trading
01/09	GSK überführt mRNA-Grippeimpfstoff in die nächste Studienphase
01/09	GSK Moves mRNA Flu Vaccine Candidate to Late-Stage Trial
28/08	Health Care Down, But not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup
28/08	BioNTech SE And Genentech Terminate Phase 2 Clinical Trial Collaboration For Autogene Cevumeran In Resected Colorectal Cancer
28/08	Wall Street voelt lichte rentevrees na 'hawkish' Jackson Hole-toespraak Warsh